Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma
Authors:
Open Access
- 16 June 2015
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 123 (9) , 531-539
Abstract
BACKGROUND: Mutations of v‐Raf murine sarcoma viral oncogene homolog B1 (BRAF) are identified in almost half of all papillary thyroid carcinomas (PTCs). These mutations are specific for PTC and may confer a worse prognosis. An immunohistochemical (IHC) stain for BRAF is commercially available and has been validated in surgical specimens. Fine‐needle aspiration (FNA) is frequently used as a diagnostic tool for risk stratification of thyroid nodules. Therefore, the authors evaluated the performance of immunostaining with the anti‐BRAF antibody VE1 on FNA direct smears.METHODS: The authors identified 51 FNA specimens that had subsequent surgical resection specimens with a diagnosis of PTC. BRAF VE1 IHC was performed on the surgical specimens to determine their mutation status. The corresponding direct smears were then stained using the same VE1 stain to assess correlation.RESULTS: Twenty‐two of the 46 included surgical specimens were positive for BRAF mutations (47.8%) by IHC, consistent with the published rates. The paired cytologic smears from these cases revealed 65.3% concordance. The overall sensitivity of BRAF staining on cytologic smears was 63.6%, and the specificity was 58.3%. Concordance rates were highest in specimens that were diagnosed as malignant or suspicious for malignancy (75% and 85.7%, respectively). The negative predictive value increased to 77.8% when suspicious for follicular neoplasm/suspicious cases were combined.CONCLUSIONS: Specimens that were malignant or suspicious on FNA were most likely to be BRAF concordant. Limitations to the interpretation of smears included low cellularity and obscuring blood, macrophages, or colloid. With further refinement, it is possible that BRAF immunocytochemistry can be applied prospectively to thyroid FNAs for risk stratification and to reduce false‐negative rates. Cancer (Cancer Cytopathol) 2015;123:531–539. © 2015 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in MelanomaAmerican Journal of Surgical Pathology, 2013
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA SamplesThe Journal of Clinical Endocrinology & Metabolism, 2011
- BRAF(V600E) mutation and the biology of papillary thyroid cancerEndocrine-Related Cancer, 2008
- Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroidCancer, 2007
- Errors in Thyroid Gland Fine-Needle AspirationAmerican Journal of Clinical Pathology, 2006
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- BRAF mutations are associated with some histological types of papillary thyroid carcinomaThe Journal of Pathology, 2004
- Fine Needle Aspiration of the Thyroid: A Cytohistologic Correlation and Study of Discrepant CasesThyroid®, 2004
- BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTCOncogene, 2003
- Fine-needle aspiration of the thyroid: Rate and causes of cytohistopathologic discordanceDiagnostic Cytopathology, 2000